AstraZeneca Canada recently announced that Lynparza (olaparib), a first-of-its-kind treatment for BRCA-mutated ovarian cancer, recently received a positive clinical recommendation for reimbursement by the pan-Canadian Oncology Drug Review (pCODR) panel. This regulatory action is an important first step toward providing Canadian women with access to the treatment. "This is a great step forward for Canadian women living with BRCA-mutated ovarian cancer," Karen Heim, vice president of patient access and established brands at AstraZeneca Canada, said in a press release. "Treatment options are limited and each day, five Canadian women die from ovarian cancer. That means every day counts, so we look forward to collaborating and expediting negotiations with the pan-Canadian Pharmaceutical Alliance, provinces and territories to ensure rapid public reimbursement for Lynparza." The decision reflects the robust clinical evidence that supports the benefits of Lynparza for use in a well-defined subset of ovarian cancer patients, AstraZeneca says. Approximately 15% of all ovarian cancer cases are due to hereditary conditions, mostly a BRCA gene mutation. Lynparza was developed as a maintenance treatment for patients with platinum-sensitive relapsed BRCA-mutated ovarian cancer.